This innovative system is set to fulfill the need for a technology that accurately determines bone density in a cost-effective manner.
Demetech is the only company in the market with DXL technology and has patented it in Europe, North America, China and Japan. Among the technology's key benefits are high precision and accuracy, rapid scanning, user friendliness and affordability.
"Due to the method used by the current standard, Dual Energy X-Ray Absorptiometry (DEXA) technology, persons with very low or high fat content get distorted results, with fat error estimated to be anywhere between 10 and 40 per cent for individual patients," notes Frost & Sullivan Research Analyst Divya B. "Demetech's DXL Calscan solves this issue by innovatively combining a dual-wavelength X-ray source with laser definition of the measurement area."
Demetech's DXL Calscan technology measures bone density in the heel, which consists of 95 per cent trabecular bone. The system measures thickness, and determines how far the photons have had to travel through fat, bone and water before they are either absorbed or not absorbed. DEXA is unable to provide this additional information. Accordingly, DXL provides a more accurate estimate of the amount of fat and therefore, a more accurate measurement of bone density.
For 2007, Demetech's R&D expenditure as a percentage of cost is estimated to be between 15 and 20 per cent. As part of its ongoing R&D initiatives, Demetech is currently conducting a new breakthrough study involving over 15,000 patient examinations, in collaboration with Stockholm-based Karolinska Institute. The study is expected to prove that Calscan can predict hip fractures as efficiently as, if not better than, axial DEXA machines, based upon cross-sectional fracture results from the same population.
"In a market characterised by the established DEXA technology, Demetech has carved a niche for itself by investing substantially in R&D activities," observes Ms. Divya. "Through a well-established distribution network and focused marketing strategies, the company is poised to fulfill the need for affordable yet accurate technology alternatives in the European bone densitometry market."
Demetech is already demonstrating this in eastern European countries such as Turkey and Serbia where it claims to be the largest selling densitometry systems company. It is also planning on launching Calscan DXL in North America in the near future and has already made inroads into South America and the Middle East.
"Demetech is set to achieve success, having developed an alternative technology that offers accuracy in detection of bone density in a cost-effective manner," concludes Ms. Divya. "By enabling the early diagnosis and treatment of osteoporosis in a primary care setting, patient quality of life may be extended using DXL Calscan."
The Frost & Sullivan Award for Technology Innovation is presented to the company that has demonstrated technological superiority within its industry. This Award recognises the ability of the company to successfully develop and introduce new technology, formulate a well-designed product family, and make significant product performance contributions to the industry.
Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
About Demetech AB
In late 2005, Scanflex International AB, a leading provider of state-of-the-art imaging systems for orthopedic surgery and products for personal radiation protection, acquired Demetech. This acquisition strengthens Demetech's position in the market. Demetech develops, manufactures and markets systems for the diagnosis and early detection of osteoporosis. Demetech, headquartered in Sweden, was founded in 1996 through funding by Venture Capitalists. Dual X-ray and Laser, commonly called DXL, was invented by a team of Swedish doctors, researchers and engineers. Demetech's DXL Calscan machine is the first instrument based on this technology. The clinical trials for Demetech's DXL Calscan system, which began in 1997 ended in 2000. Demetech's first DXL Calscan system was sold in Sweden in 2001 and since then they have sold 100 units in Sweden. In the year 2004, Demetech obtained the U.S. Food and Drug Administration clearance for Calscan.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community, by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.
For further information, please contact:
John Elliott, Dir. of Marketing & Sales, Demetech AB, Taby, Sweden
T: +46-733-105099, info[.]demetech.com